Skip to main content
Premium Trial:

Request an Annual Quote

Myriad Genetics First Quarter Revenues Up 22 Percent

NEW YORK, Nov. 7 – Myriad Genetics said Wednesday its fiscal first quarter revenues increased 22 percent to $13.2 million, compared with $10.8 million a year ago, boosted by strong sales of the company’s diagnostic products.

Myriad of Salt Lake City said that product revenues alone increased 81 percent in the quarter to $5.5 million. The company manufactures the BracAnalysis product for breast and ovarian cancer and the Colaris product for colon and uterine cancer.

The company said that later this month it would launch a new predictive product for melanoma, which should further strengthen revenue growth.

"Myriad's predictive medicine products group demonstrated strong revenue growth during the past quarter, contributing to the Company's smaller than expected loss," Peter Meldrum, CEO of Myriad Genetics, said in a statement.

"The strong revenue growth assisted Myriad in maintaining a modest cash burn rate while investing significantly in our pharmaceutical development programs," he added. 

During the quarter, Myriad started a drug development program for Hepatitis C and announced the discovery of a new drug designed to prevent HIV infection. In addition, Myriad also recently said that its cancer therapeutics program was progressing.

The company also announced that it would collaborate with Pharmacia to develop and commercialize pharmacogenomics technologies. 

During the quarter, the company's research and development expenses fell slightly to $8.3 million, compared with $8.8 million a year ago, although overall costs were up to $16.2 million, compared with $14.0 million in fiscal first-quarter last year, as selling, general, and administrative costs rose.

Nevertheless, operating losses in the first fiscal quarter narrowed to $3.0 million, compared with $3.2 million last year.    

Net losses for the first quarter narrowed to $1.2 million, or five cents a share, compared with $2.1 million, or nine cents a share, in the year ago period.

At the end of September Myriad had $136 million in cash and investments.

The Scan

Interfering With Invasive Mussels

The Chicago Tribune reports that researchers are studying whether RNA interference- or CRISPR-based approaches can combat invasive freshwater mussels.

Participation Analysis

A new study finds that women tend to participate less at scientific meetings but that some changes can lead to increased involvement, the Guardian reports.

Right Whales' Decline

A research study plans to use genetic analysis to gain insight into population decline among North American right whales, according to CBC.

Science Papers Tie Rare Mutations to Short Stature, Immunodeficiency; Present Single-Cell Transcriptomics Map

In Science this week: pair of mutations in one gene uncovered in brothers with short stature and immunodeficiency, and more.